Session Description: Influenza remains a leading cause of morbidity and mortality among older adults, particularly those residing in long-term care (LTC) settings. Influenza vaccine effectiveness is reduced among frail older adults. Despite recognition of the impact of influenza and the reduced vaccine effectiveness in older adults, there is almost no influenza vaccine research conducted among frail LTC residents. Increased vaccine research among this population is desperately needed. This session will describe the limitations of influenza vaccination of LTC residents, describe the results of the first completed study comparing regular versus high dose influenza vaccine among LTC residents, review challenges faced in the conduct of vaccine related research in the LTC setting, and identify future influenza vaccine research needs.
Discuss the limited effectiveness of influenza vaccines among long term care residents.
Describe the results of a recently conducted trial of regular versus high dose influenza vaccine among frail long term care residents.
Explain challenges encountered in conducting vaccine research in long term care populations.
Identify future influenza vaccine research questions for the long term care population.
Speaker(s): David A. Nace, MD, MPH, CMD
Disclosure(s): Sanofi Pasteur; Research grant support, Investigator initiated study of regular versus high dose influenza vaccine in frail LTC residents.
Reference(s): Nace, DA, Drink P, Poland G. AMDA LTC Information Series: Immunization in the Long-Term Care Setting. AMDA. Columbia, MD, AMDA. 2010 Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 2012;12(1): 36-44. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Archives of Internal Medicine 2006; 166(10): 1121-1127. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. Journal of Infectious Diseases 2009;200(2): 172-180.
MD, MPH, CMD,
Associate Professor of Medicine & Director of Long-Term Care,
University of Pittsburgh
You must be logged in and own this session in order to